A Complete History of Hyperbaric Medicine

A chronological history of compressed-air and hyperbaric oxygen medicine, from the seventeenth-century speculations of a British clergyman to the telomere research of Israeli neurologists — covering every documented milestone, institution, and physician along the way.

Prologue: The Pressure Beneath the Medicine

Hyperbaric oxygen therapy — the practice of breathing pure oxygen inside a chamber pressurized beyond sea level — is at once ancient in its impulse and modern in its science. The impulse is as old as medicine itself: that the atmosphere surrounding a patient might be altered to heal. The science required centuries to catch up. This history traces that long arc from a seventeenth-century proposal that was almost certainly never built, through the gilded pneumatic institutes of nineteenth-century France, the Steel Ball Hospital that once loomed over Lake Erie, to the randomized controlled trials now probing stroke recovery and long COVID in Tel Aviv and Gothenburg. It is a story of visionaries, charlatans, martyrs, Nobel laureates, and Navy divers — and of a therapy that was condemned as quackery four times before it was eventually proven to save lives.

Part I: Origins — The Age of Compressed Air (1662–1877)

1662 — Nathaniel Henshaw and the Domicilium

The first recorded proposal for a pressurized medical chamber belongs to Nathaniel Henshaw (1628–1673), a British physician and clergyman. In his 1662 treatise Aero-Chalinos, Henshaw described a sealed room he called the domicilium, intended to raise or lower atmospheric pressure using a "very large pair of organ bellows." His theory was simple and pre-Lavoisian: high pressure for acute illnesses, low pressure for chronic ones. "In times of good health," he wrote, "this domicilium is proposed as a good remedy for assisting digestion, promoting insensible respiration, facilitating breathing and expulsion of sputum, and, consequently, is of excellent utility in preventing most pulmonary infections."

Oxygen would not be discovered for another century, so Henshaw had no concept of partial pressures — he was reasoning from humoral instinct, not gas physics. Modern scholarship has been skeptical of whether the domicilium was ever built. A 2024 paper in Undersea and Hyperbaric Medicine by Kevin Bove concludes, after meticulous analysis of Henshaw's original text, that the chamber was never constructed: the engineering challenges of pressure-sealing a glass-windowed room with 1660s technology were insurmountable, and the decompression exposures Henshaw proposed would likely have been lethal given the complete absence of knowledge about nitrogen saturation. Henshaw's legacy is, in the end, conceptual rather than clinical — the first person to imagine that ambient pressure could be a medical variable.

1834–1877 — The French Pneumatic Renaissance

The practical history of hyperbaric medicine begins not in seventeenth-century England but in nineteenth-century France. In 1834, the French physician Victor Théodore Junod built a copper-sphere chamber capable of reaching 2–4 atmospheres absolute (ATA), designed with the help of engineering principles from the steam-engine tradition. Junod called his treatment le bain d'air comprimé — the compressed-air bath — and claimed it increased circulation to the brain and internal organs, producing sensations of well-being and heightened mental clarity. The chamber was used to treat pulmonary afflictions at a time when tuberculosis killed one in seven Europeans. Whether the treatment worked for TB is doubtful; but the observation that pressurized oxygen elevated mood and improved breathing in patients with pulmonary compromise was not entirely wrong. (InTechOpen: Historical Aspects of Hyperbaric Physiology and Medicine)

In 1832, before Junod's clinical work, Emile Tabarie had presented a design to the French Academy of Sciences: a spherical cast-iron chamber with a hydraulic steam compressor, a ventilation pipe, and — crucially — an antechamber that allowed the treating physician to enter and exit without disrupting the pressurization. The floor was carpeted, the antechamber stocked with books, newspapers, and drinks. This was not merely engineering ingenuity; it was a statement about the social context of the therapy. The pneumatic chamber was, from the very beginning, a spa as much as a clinic. (Asthma History Blog: 1870–1900 Pneumatic Chambers)

In 1837, Charles-Gabriel Pravaz — better known today for his invention of the hypodermic syringe — constructed in Lyon the largest hyperbaric chamber yet built, capable of accommodating twelve patients simultaneously. Pravaz treated tuberculosis, laryngitis, tracheitis, pertussis, cholera, conjunctivitis, deafness, and rickets — a list that reveals more about the therapeutic desperation of pre-bacteriological medicine than about any rational theory of hyperbaric physiology. He was nonetheless pioneering the first multi-patient pressurized medical facility in history. (InTechOpen)

Between 1837 and 1877, pneumatic institutes proliferated across Europe: Berlin, Amsterdam, Brussels, London, Vienna, Milan, and Montpellier all hosted facilities. Bertin wrote the field's first textbook on compressed-air therapy in 1855 and built his own chamber. Contemporaneous German physicians — including Lange, who constructed a cylindrical chamber for four persons with cooling and heating systems — refined the technical apparatus considerably. These were luxurious establishments patronized by the European upper-middle class, offering what we might now recognize as a proto-spa or sanatorium experience. Patients seeking relief from asthma, consumption, diphtheria, and whooping cough sat in carpeted, ventilated pressure chambers while physicians administered breathing treatments. (BioBarica: History of the Hyperbaric Chamber)

1877 — Fontaine's Mobile Operating Theater

The pneumatic era reached its most dramatic expression in 1877, when French surgeon J.A. Fontaine constructed the first mobile hyperbaric operating room — a pressurized surgical theater mounted on wheels. Over a three-month period, Fontaine performed 27 surgical operations inside this chamber, noting that the elevated ambient pressure increased the apparent potency of nitrous oxide anesthesia and improved patient oxygenation during procedures. He calculated that compressed air at two atmospheres provided the equivalent of breathing 42% oxygen at sea level, before supplemental oxygen was practically available. Encouraged, Fontaine conceived an even grander structure: a hyperbaric surgical amphitheater accommodating 300 patients at once. He would never build it. Fontaine died in an accident at the Pneumatic Institute, becoming — with bitter irony — the first physician to be martyred in the history of hyperbaric medicine. (InTechOpen)

Part II: Science Arrives — Caissons, Gas Laws, and the Physiologists (1854–1908)

1854–1882 — The Caisson Disaster and the Birth of Hyperbaric Physiology

The true engine of hyperbaric science was not the spa but the construction site. In the mid-nineteenth century, civil engineers began sinking pneumatic caissons — sealed, pressurized underwater working chambers — to lay the foundations of the world's great bridges. Workers who spent hours at 2–4 atmospheres in these caissons, then ascended to the surface, began dying and being paralyzed in alarming numbers. The condition was called "the bends" — after the bent, limping posture adopted by sufferers — or "caisson disease." The Eads Bridge in St. Louis (1869–1874) and the Brooklyn Bridge in New York (1870–1883) were particular killing grounds. Andrew Smith, the physician overseeing Brooklyn Bridge construction, documented 110 cases among the 600 caisson workers, with no recompression treatment available on site. Workers walked with the stoop of the "Grecian bend" — the fashionable female posture of the day — and some died within hours of leaving the chamber. (PubMed: Caisson disease during Eads and Brooklyn Bridge construction)

In 1889, during construction of the Hudson River Tunnel, engineer E.W. Moir installed the first dedicated recompression lock for treatment, reducing the death rate from decompression sickness from 25% to nearly zero by recompressing affected workers to two-thirds of working pressure for 25–30 minutes, then decompressing slowly. Moir published these results in 1896, providing the earliest systematic clinical data on recompression as therapy. The stage was now set for the physiologists.

1878 — Paul Bert and La Pression Barométrique

The most important scientific figure in the entire history of hyperbaric medicine is the French physiologist Paul Bert (1833–1886). A student of Claude Bernard — who vacated his chair at the Sorbonne specifically for Bert in 1868 — Bert spent years studying the physiological effects of pressure in a systematic, experimental, and quantitative manner. His magnum opus, La Pression Barométrique: Recherches de Physiologie Expérimentale, published in 1878, remains one of the most comprehensive single works in the history of physiology. (LITFL: Paul Bert)

Bert's discoveries were transformative:

1. He proved that nitrogen causes decompression sickness. Using dog experiments at 7–10 ATA with rapid decompression, he observed gas bubbles — consisting primarily of nitrogen that had dissolved under pressure and was liberated on rapid ascent — in the tissues and right side of the heart. He demonstrated that slow decompression over 1–2 hours prevented this, confirming Paul Bert's nitrogen bubble hypothesis as the mechanism of caisson disease. (Wilderness Medicine Magazine: History of Diving Part 3)

2. He discovered oxygen toxicity. By exposing animals to pure oxygen at elevated pressures, Bert observed that exposure to partial pressures of oxygen above approximately 1.75 ATA produced convulsions and death. The underlying mechanism, he determined, was hyperexcitability of the spinal cord. This phenomenon of central nervous system oxygen toxicity — a seizure disorder induced by elevated oxygen partial pressure — has been known ever since as the "Paul Bert effect." It remains the primary safety concern in clinical hyperbaric medicine today. (LITFL: Paul Bert)

3. He laid the thermodynamic foundations. Bert stated his central principle with unusual clarity: "Oxygen tension is everything; barometric pressure in itself does nothing or almost nothing." In doing so, he reframed hyperbaric medicine from a question of mechanical pressure to a question of dissolved gas chemistry — anticipating Dalton's and Henry's laws as the organizing framework for everything that would follow.

Bert experimented on himself in a pressure chamber, noting headache, dizziness, and darkened vision at low pressure — all relieved by oxygen inhalation. He trained French balloonists in pressure physiology and provided them with oxygen bags for high-altitude ascents. He was awarded the Académie des Sciences biennial prize of 20,000 francs in 1875. He died in 1886, shortly before he could witness the clinical application of his discoveries. (Sophia Rare Books: La Pression Barométrique)

In the years after Bert, J. Lorrain Smith identified a complementary toxic syndrome: prolonged exposure to oxygen at near-atmospheric pressures causes progressive lung damage through alveolar edema — the "Lorrain Smith effect" or pulmonary oxygen toxicity. Together, the Paul Bert effect (CNS, high pressure, short duration) and the Lorrain Smith effect (pulmonary, low pressure, prolonged duration) define the two boundaries within which all therapeutic hyperbaric oxygen use must operate.

1908 — John Scott Haldane and Staged Decompression

The missing piece was a practical, quantitative method for allowing compressed-air workers and divers to ascend safely. In 1905, the British Royal Navy commissioned physiologist John Scott Haldane — already famous for studies of respiratory physiology and industrial gas hazards — to develop a systematic decompression protocol. Working at the Lister Institute of Preventive Medicine in London with pathologist Arthur Edwin Boycott and Royal Navy diver Lieutenant Guybon C.C. Damant, Haldane conducted experiments on 85 goats in a steel compression chamber over two years.

His key insight was deceptively simple: the body could safely tolerate a sudden halving of ambient pressure without forming dangerous nitrogen bubbles, regardless of starting depth. From this "two-to-one" ratio, Haldane derived his staged decompression model — a series of stops at calculated depths, each lasting a calculated duration based on the nitrogen half-times of fast and slow tissues. He submitted a confidential report to the Admiralty in August 1907 and published the tables openly in 1908. (EBSCO: Haldane Develops Stage Decompression)

The tables were immediately adopted by the Royal Navy and — following a successful 1915 submarine salvage off Honolulu at 50 fathoms — by navies worldwide. Decompression sickness among naval divers virtually disappeared. Haldane's five-compartment half-time model is the direct ancestor of every modern dive computer algorithm in use today. His work also established the framework for hyperbaric treatment tables: if staged decompression prevented nitrogen bubble formation, then recompression followed by staged decompression could treat it. This logic governed hyperbaric medicine for the next fifty years. (CMAS: Haldane 1908)

Part III: The American Experiment — Corning, Cunningham, and the Steel Ball (1860–1937)

1860–1891 — North American Compressed-Air Medicine

The first hyperbaric chamber on the North American continent was built in 1860 in Oshawa, Ontario, Canada. A year later, in 1861, Dr. James Leonard Corning — a New York neurologist already known for pioneering work in spinal anesthesia — established a compressed-air facility in New York City, reportedly inspired by witnessing severe decompression illness among workers on the Hudson Tunnel. Corning's chamber was an 8-foot-by-30-foot cylindrical tube; he treated decompression sickness, caisson workers, and a broader range of neurological disorders. His treatments for non-decompression conditions were largely unsuccessful, but his chamber represented the formal arrival of hyperbaric medicine in the United States. (HMP Global Learning Network: HBOT Brief History)

1918 — Dr. Orval J. Cunningham and the Spanish Influenza

The most consequential American chapter in pre-modern hyperbaric history begins with a devastating pandemic. In 1918, the Spanish influenza was killing tens of millions worldwide. Dr. Orval J. Cunningham, chief anesthetist at the University of Kansas School of Medicine, made a critical clinical observation: patients in low-lying Kansas City were surviving the flu at higher rates than patients in the thinner air of Denver. The physiological inference — that barometric pressure affected mortality in cardiorespiratory illness — was not unreasonable. Hypoxia killed flu patients as pneumonia flooded their lungs; more atmospheric pressure meant more dissolved oxygen.

Cunningham built a hyperbaric chamber at the University of Kansas Hospital in 1918 and placed a young resident physician suffering from the flu into the chamber at 2 ATA. The physician recovered. Cunningham interpreted this success as proof of his theory that anaerobic microorganisms — which could not survive in high-oxygen environments — were responsible for influenza, diabetes, cancer, and syphilis. He was both right (about the oxygen-killing anaerobes) and catastrophically wrong (about the diseases he thought were caused by them). The AMA would later note, with some exasperation, that the extra oxygen his chambers delivered could have been provided from an oxygen tank at a fraction of the cost and complexity. (Midtown KC Post: Steel Tank at 33rd and Harrison) (Cleveland Historical: Cunningham Sanitarium)

Cunningham moved to Kansas City, built an 88-foot-long, 10-foot-diameter cylindrical chamber, and began treating patients — mostly affluent ones — for a remarkable range of conditions. Wealthy patients began arriving from across the country. Among them was H.H. Timken Jr., scion of the Timken Roller Bearing Company fortune of Canton, Ohio, who believed Cunningham's compressed-air treatment had cured his illness (possibly uremia). The younger Timken was so impressed that his father, Henry H. Timken, offered Cunningham one million dollars to scale up his operation.

1928 — The Steel Ball Hospital

The result was the most extraordinary medical structure ever built: a steel sphere, five stories tall, 65 feet in diameter, weighing 900 tons, erected along the shore of Lake Erie in Cleveland, Ohio, near East 185th Street at 18485 Lake Shore Boulevard. It was engineered by Alois Hauser, chief engineer of the Timken Company, and constructed by the Melbourne Construction Company over nearly a year of hard labor. The facility opened its doors to patients on December 1, 1928. (Cleveland Historical: Cunningham Sanitarium)

The interior was not a spartan clinical facility. It contained 38 to 60 rooms (accounts vary), a first-floor dining room, crystal-chandeliered recreation rooms, a reception hall on the top floor, 350 portholes for natural light, an elevator, and a climate-controlled environment maintained at 68°F with 65% humidity. The entire building was pressurized to approximately 30 psi — roughly double sea-level pressure. Patients could stay for up to two weeks at elevated pressure, alternating with periods at normal pressure. Cunningham treated diabetes, cancer, pernicious anemia, hypertension, and syphilis.

The American Medical Association was not amused. In May 1928 — while the Steel Ball was still under construction — the Journal of the American Medical Association published a critical review condemning Cunningham's claims as "altogether without scientific proof." Repeated requests for Cunningham to submit clinical evidence were declined. In 1930, the Cleveland Medical Society and the AMA forced closure of his Kansas City facility. By 1933, the economic depression had forced Cunningham to sell the Cleveland sphere for $500,000 to a 20-year-old protégé, James Rand Jr., son of the president of Remington Rand. Rand renamed it the Ohio Institute of Oxygen Therapy; it failed. The building changed hands again in 1936 and briefly operated as Boulevard Hospital before closing for financial reasons. The steel was sold for $25,000 in scrap — under orders from the U.S. War Production Board — and the great sphere was dismantled on March 31, 1942, to feed the wartime industrial machine. The site is today occupied by Villa Angela-St. Joseph High School. (Lakeside Press: Cunningham's Steel Ball) (OnePager ICU: Cunningham's Spherical Sanitarium)

The Steel Ball Hospital was the largest hyperbaric chamber ever built, and it remains so. Its ghost haunts hyperbaric medicine's institutional memory as a monument to the dangers of a therapy applied without evidence — and, simultaneously, as an eerie anticipation of the modern hyperbaric hospital, where patients live for weeks at elevated pressure undergoing daily treatments.

Part IV: Scientific Foundations — The First Evidence-Based Era (1937–1965)

1937 — Behnke and Shaw: Oxygen for Decompression Sickness

The transition from compressed-air therapy to oxygen therapy began in Germany in 1917, when engineers Bernhard and Heinrich Dräger first applied pressurized oxygen (rather than compressed air) to treat diving accidents. Their protocols were operationalized in the United States in 1937–1939 by Dr. Albert R. Behnke and Louis Shaw of the U.S. Navy, who demonstrated that pure oxygen at elevated pressure was more effective than compressed air for treating decompression sickness, and began developing the nitrogen-oxygen treatment mixtures that evolved into the U.S. Navy Treatment Tables still in use today. (HMP Global: HBOT Brief History) By 1939, the U.S. Navy had formally adopted hyperbaric oxygen therapy for decompression sickness — the first institutional, evidence-based approval of what we now call HBOT.

1955–1960 — Ite Boerema and the Rebirth of Hyperbaric Medicine

The true renaissance of scientific hyperbaric medicine — what historians call the "Boerema era" — begins in the 1950s in Amsterdam. Dr. Ite Boerema, Professor of Surgery at the University of Amsterdam and a man who regarded surgery as "engineering in medicine," was searching for a way to keep pediatric patients with complex congenital heart defects alive during open-heart surgery, which requires temporarily stopping the heart. The limiting factor was the brain's oxygen demand: at normal pressure, a patient in cardiac arrest survives only 3–4 minutes before irreversible neurological damage occurs.

Boerema recognized, from Henry's Law, that oxygen dissolved in plasma rises in proportion to ambient pressure — independently of hemoglobin. If the plasma itself could carry enough oxygen to sustain life, cardiac arrest could last longer, allowing more complex surgery. Beginning in 1956, he and his team at the University of Amsterdam conducted a series of experiments with the Royal Dutch Navy, operating on piglets inside a hyperbaric chamber at 3 ATA. In 1959, Boerema published the experiment that would make him the father of modern hyperbaric medicine: "Life Without Blood." (PubMed: Life Without Blood)

The procedure was audacious: the team rapidly exsanguinated swine to hemoglobin levels as low as 1 g/dL — incompatible with life at normal pressure — replacing the blood with Ringer's lactate solution. Inside the hyperbaric chamber at 3 ATA of 100% oxygen, the oxygen dissolved in the plasma alone was sufficient to sustain the animals. The pigs survived. They were re-transfused with their own blood, the chamber was depressurized, and they walked off unimpaired. (PMC: HBOT in ATLS/ACLS resuscitative context) The experiment validated, more dramatically than any previous work, the fundamental physics that Bert had described: under sufficient pressure, dissolved oxygen in plasma can replace the oxygen normally transported by hemoglobin.

Boerema's work launched a decade of intense international interest in hyperbaric oxygen for cardiac surgery. Major hyperbaric operating suites were built at Duke University, Mount Sinai Hospital in New York, Presbyterian Hospital, Edgewater Hospital in Chicago, Good Samaritan in Los Angeles, St. Barnabas in New Jersey, Harvard Children's Hospital, and St. Luke's in Milwaukee. (BioBarica: Hyperbaric Medicine History)

1961 — Brummelkamp and Gas Gangrene

Boerema's colleague at the University of Amsterdam, W.H. Brummelkamp, published in 1961 the first systematic evidence that hyperbaric oxygen could inhibit clostridial (anaerobic) infections — specifically Clostridium perfringens, the bacterium responsible for gas gangrene, a rapidly fatal tissue-destroying infection that had killed hundreds of thousands of soldiers in World War I and II. Brummelkamp demonstrated that at 3 ATA of oxygen, clostridial toxin production was suppressed and the bacteria could no longer proliferate. (PubMed: Treatment of clostridial infections with hyperbaric oxygen)

This was the first application of HBOT grounded in a rigorous microbiological mechanism. By 1960, a gas-gangrene patient had been treated successfully in Amsterdam's hyperbaric chamber — the first explicitly modern therapeutic use of the modality. (InTechOpen) The September 1961 First International Congress on HBOT, held in Amsterdam, formalized the field's emergence as a discipline.

1962 — Smith and Sharp: Carbon Monoxide Poisoning

In Glasgow, Scotland, in 1962, G. Smith and G.R. Sharp published the first systematic evidence that hyperbaric oxygen was effective for carbon monoxide poisoning — at that time a leading cause of accidental and intentional death. Carbon monoxide binds hemoglobin with 200 times the affinity of oxygen, displacing it and causing cellular asphyxiation; breathing 100% oxygen at 2.5–3 ATA accelerates CO elimination from hemoglobin by approximately tenfold compared with room air, restoring tissue oxygenation rapidly. Of 70 patients treated by Smith and Sharp with HBO at 3 ATA for 90 minutes, only two died — a then-unprecedented survival rate. (JAMA Surgery: Carbon Monoxide Poisoning Treatment by Hyperbaric Oxygenation)

The Glasgow results attracted international attention and effectively launched the modern evidence-based era of HBOT. They also established carbon monoxide poisoning as one of the therapy's most durable approved indications — a status it retains today.

Part V: Institutionalization — The UHMS, Medicare, and Wound Care (1963–1999)

1963 — The Mitsui Miike Coal Mine Disaster

On November 9, 1963, at the Miike Mikawa Coal Mine in Omuta, Kyushu, Japan — operated by Mitsui Coal Mining Company — a coal dust explosion released a massive cloud of carbon monoxide gas. The disaster killed 458 workers and resulted in 839 cases of CO poisoning, one of the largest carbon monoxide mass casualty events in history. The Department of Neuropsychiatry at Kumamoto University School of Medicine immediately began periodic medical examinations of survivors and continued them for 33 years until the mine's closure in 1997. This unprecedented long-term follow-up of over 800 CO-poisoned patients — published finally in the Journal of Undersea and Hyperbaric Medicine in 2023 — remains the largest longitudinal study of carbon monoxide poisoning in medical history. (PubMed: Long-term effects of CO poisoning at Miike Coal Mine) The disaster accelerated Japanese investment in hyperbaric facilities and catalyzed systematic research into CO-related neurological sequelae — contributing to the emerging global evidence base.

1963 — Duke University's Chambers

In 1963, Duke University installed its first hypo-hyperbaric research chamber, initiating a research program that would become one of the most prolific in hyperbaric science. In 1968, the F.G. Hall Laboratory was completed — six large chambers capable of simulating depths of 1,000 feet of seawater and altitudes of 100,000 feet — under the direction of Dr. Herbert Saltzman. Under the subsequent directorship of Dr. Peter B. Bennett, Duke conducted the Atlantis series of deep manned dives between 1978 and 1984, simulating depths of up to 3,600 feet of seawater (69.5 ATA) in a series of landmark saturation dives — the deepest ever conducted in a laboratory setting — generating over 1,000 scientific publications. (Duke Anesthesiology: History of Duke Chambers)

1967 — The Founding of the Undersea Medical Society

By 1967, the field of hyperbaric and diving medicine had matured sufficiently to require a dedicated scientific organization. Six physicians — naval officers and scientists including Dr. Albert R. Behnke, Dr. Christian J. Lambertsen, Earl H. Ninow, Edward L. Beckman, Jack L. Kinsey, and Walter F. Mazzone — met formally on April 10, 1967 in Washington, D.C. to establish the Undersea Medical Society (UMS), with Lambertsen, working from laboratories at the University of Pennsylvania, writing the founding constitution and organizing charter membership. The first annual scientific meeting followed on May 9, 1968, with a congratulatory telegram from Vice President Hubert Humphrey, who chaired national councils on marine and space technology. (UHMS: 40-Year History Booklet)

In 1986, reflecting the field's expansion beyond diving physiology, "hyperbaric" was added to the Society's name, and it became the Undersea and Hyperbaric Medical Society (UHMS) — the primary international scientific and regulatory authority for hyperbaric medicine it remains today. The UHMS now serves members in more than 67 countries and publishes the peer-reviewed Journal of Undersea and Hyperbaric Medicine. (UHMS: About the UHMS)

1970s — Medicare Coverage and the Formal Approval Process

In 1976, the U.S. Centers for Medicare & Medicaid Services (CMS) began reimbursing hyperbaric oxygen therapy for select indications — the formal beginning of HBOT as a covered medical service in the United States. The UHMS developed a formal process for evaluating indications based on the weight of evidence, creating a Committee on Hyperbaric Oxygen Therapy in the 1970s whose approved-indications list became the benchmark accepted by Medicare and private insurers. The initial covered indications included decompression sickness, arterial gas embolism, carbon monoxide poisoning, clostridial myonecrosis, crush injuries, acute traumatic peripheral ischemia, compromised skin grafts, refractory osteomyelitis, and acute peripheral arterial insufficiency. (CMS: Hyperbaric Oxygen Therapy for Hypoxic Wounds)

1983–1985 — Robert Marx and Osteoradionecrosis

In the early 1980s, Dr. Robert Marx, maxillofacial surgeon at the University of Miami, undertook the first systematic investigation of HBOT for radiation-induced tissue damage. Radiation therapy for head and neck cancers causes progressive obliterative endarteritis — a closing of the small blood vessels — leaving hypoxic, hypovascular, hypocellular ("3-H") tissue that cannot heal normally. Marx's landmark 1985 randomized prospective clinical trial, published in the Journal of the American Dental Association, demonstrated that hyperbaric oxygen reduced the incidence of osteoradionecrosis from 30% with penicillin alone to 5% with HBO — a 6-fold reduction. (Marx et al. JADA 1985) His "20/10 protocol" (20 pre-operative and 10 post-operative hyperbaric sessions for patients undergoing surgery in irradiated tissue) became the standard of care. Marx eventually treated over 400 patients and established the definitive protocols for radiation tissue injury — another durable indication in UHMS and Medicare coverage.

1988–1999 — The Wound Care Era: Davis, Hunt, and the Oxygen-Wound Hypothesis

The theoretical underpinning for HBOT in wound healing was laid by Thomas K. Hunt and colleagues at the University of California San Francisco from the late 1960s through the 1980s, demonstrating that oxygen tension in wound tissue was the principal determinant of collagen synthesis, angiogenesis, and resistance to infection. The landmark textbook Problem Wounds: The Role of Oxygen, co-edited by J.C. Davis and T.K. Hunt and published in 1988, synthesized this evidence and established the oxygen-wound axis as the theoretical framework for all subsequent HBOT wound-healing applications. (DVM360: History of Hyperbaric Oxygen Therapy)

The 1980s and 1990s saw the emergence of the modern wound care era: hospital-based hyperbaric wound centers proliferated across the United States, treating diabetic foot ulcers, venous stasis ulcers, and radiation wounds. Studies showed that HBOT reduced major amputation rates in diabetic foot ulcer patients by 75% compared with standard care, stimulating CMS to add diabetic wound care (Wagner Grade III or higher) to Medicare coverage in 2002. (CMS: HBOT for Hypoxic Wounds)

Part VI: Expansion and Controversy — Off-Label Applications (2000–2010)

2000 — ABMS Recognition and Subspecialty Status

In 2000, the American Board of Medical Specialties recognized hyperbaric medicine as a subspecialty of both emergency medicine and preventive medicine, establishing board certification requirements and formalizing the credentialing pathway for hyperbaric physicians. This institutional recognition accompanied a period of rapid growth: by the early 2000s, more than 500 hyperbaric facilities operated in the United States.

2001–2010 — The Off-Label Controversy: Autism, Cerebral Palsy, TBI

The same growth that legitimized hyperbaric medicine in wound care also attracted off-label applications of questionable scientific basis. In the mid-2000s, practitioners began advertising HBOT as a treatment for autism spectrum disorder, cerebral palsy, and traumatic brain injury (TBI), charging thousands of dollars per course without published controlled evidence. The FDA issued consumer warnings, the UHMS published a position paper against HBOT for autism, and major pediatric neurology organizations published rebuttals. (CPRN: FDA Warning Against HBOT for Cerebral Palsy) (PubMed: Hyperbaric oxygen and cerebral palsy)

The TBI question was more nuanced. Dr. Paul Harch of Louisiana State University Health Sciences Center had been using HBOT for ischemic brain injury and neurological disorders since the early 1990s, and in 2011–2012 published clinical data on blast-induced persistent post-concussion syndrome (PCS) and PTSD in military veterans, reporting significant improvements in symptoms, cognitive testing, and SPECT brain imaging following 29 sessions at 1.5 ATA. (PMC: Hyperbaric oxygen in chronic traumatic brain injury) Harch's work attracted substantial attention from veterans' advocacy groups and initiated a series of military-funded clinical trials that produced conflicting results — some positive, some neutral, with interpretation complicated by sham protocol design. The TBI/HBOT question remained clinically unresolved through 2024 despite nearly two decades of research.

2006 — Stem Cell Mobilization

In 2006, Dr. Stephen Thom at the University of Pennsylvania published findings in the American Journal of Physiology demonstrating that HBOT doubled the circulating levels of stem cells (CD34+ cells) in the blood of healthy subjects — the first evidence that hyperbaric oxygen could mobilize endogenous stem cells from bone marrow. (InTechOpen) This discovery opened a new mechanistic pathway for understanding why HBOT benefited neurological conditions, wound healing, and radiation injury, and initiated a decade of research into HBOT's genomic and cellular mechanisms.

Part VII: The Modern Renaissance — Neuroplasticity, Aging, and Long COVID (2010–Present)

2011 — UHMS Adds Idiopathic Sudden Sensorineural Hearing Loss

In October 2011, the UHMS Board of Directors ratified the addition of idiopathic sudden sensorineural hearing loss (ISSHL) as an approved HBOT indication — the most recent formal addition at the time of this writing. Sudden hearing loss, defined as ≥30 dB loss across three adjacent frequencies occurring within 72 hours, has no established cause in approximately 90% of cases. Evidence from multiple randomized controlled trials — and a Cochrane Review — demonstrated that HBOT, particularly when combined with oral corticosteroids within 14 days of symptom onset, significantly improved hearing outcomes compared with steroids alone. The UHMS designated the evidence as Class IIa with Level A support (multiple randomized trials). (UHMS: Idiopathic Sudden Sensorineural Hearing Loss) The European Consensus Conference on HBOT affirmed the same indication in April 2016. (PMC: Idiopathic SSHL — Is Hyperbaric Oxygen Effective?)

2013 — Efrati and the Post-Stroke Neuroplasticity Trials

The most significant contribution to hyperbaric neurology in the twenty-first century comes from Prof. Shai Efrati at the Sagol Center for Hyperbaric Medicine and Research, Assaf Harofeh Medical Center, Zerifin, Israel (affiliated with Tel Aviv University's Sackler School of Medicine). In January 2013, Efrati published in PLOS ONE the first prospective, randomized controlled trial of HBOT for chronic post-stroke neurological deficits. Seventy-four patients who had suffered strokes 6–36 months earlier, with persistent motor dysfunction, were randomized to 40 sessions of HBOT (90 minutes, 2 ATA, 100% oxygen, five days per week) or a control period. (PMC: Hyperbaric Oxygen Induces Late Neuroplasticity in Post-Stroke Patients)

The results were striking: HBOT produced significant improvements in neurological function and quality of life in both treated groups, while no improvement occurred during control periods. SPECT brain imaging revealed elevated activity in previously silent but anatomically intact brain regions — "idling neurons" that had lost function after stroke but remained structurally alive. Efrati's group proposed a mechanistic model: HBOT activates neuroplasticity by providing sufficient oxygen to reawaken dormant but viable brain tissue in the "ischemic penumbra" — regions of discrepancy between anatomy (CT) and physiology (SPECT). This framework — treating HBOT as an angiogenic and neuroplastic stimulus rather than simply an oxygen delivery mechanism — has driven the Israeli research program ever since.

2020 — Telomere Lengthening and Senescent Cell Clearance

In November 2020, Efrati's group published a landmark prospective trial in the journal Aging, demonstrating for the first time in humans that repeated HBOT sessions could reverse two cellular hallmarks of aging: 1) telomere shortening, and 2) accumulation of senescent cells ("zombie cells"). Thirty-five healthy adults aged 64 and older completed 60 daily HBOT sessions (90 minutes, 2 ATA, 100% oxygen). (PMC: HBOT Increases Telomere Length and Decreases Immunosenescence)

Telomere lengths in B cells increased by up to 37.63% above baseline; T-helper cell senescence was reduced by up to 37%. The findings were described by the authors as the first in vivo demonstration that a non-pharmacological intervention could increase telomere length in human immune cells. The mechanisms proposed involve HBOT-induced upregulation of telomerase activity and activation of senolytic pathways through intermittent hyperoxygenation. The study attracted international media attention and significant scientific controversy — critics noted the small sample size and absence of a sham-controlled group — but it positioned HBOT at the frontier of anti-aging biology.

2022 — Cognitive Enhancement in Healthy Aging Adults

Building on the telomere work, Efrati and Dr. Amir Hadanny published a 2020 randomized controlled trial demonstrating that 60 daily HBOT sessions significantly improved cognitive function in healthy older adults (>64 years), with the most striking improvements in attention (net effect size 0.745) and information processing speed (0.788). Cerebral blood flow in the right superior medial frontal gyrus and other prefrontal regions increased significantly in the HBOT group compared with controls. (PubMed: Cognitive enhancement of healthy older adults using HBOT) A subsequent 2022 randomized controlled trial published in Nature Scientific Reports showed that HBOT improved neurocognitive outcomes, psychiatric symptoms, sleep, and pain in patients with post-COVID-19 syndrome, with associated improvements in brain MRI perfusion in the supramarginal gyrus, left supplementary motor area, and right insula. (Nature: HBOT improves neurocognitive outcomes in post-COVID)

2021–2025 — Long COVID and HBOT

The emergence of post-acute sequelae of SARS-CoV-2 infection ("Long COVID") after 2020 opened a new and urgent research frontier for HBOT. Long COVID is characterized by persistent fatigue, cognitive impairment ("brain fog"), dyspnea, pain, and psychological symptoms lasting months to years after acute SARS-CoV-2 infection, affecting an estimated 65 million people globally. The mechanistic hypothesis — that HBOT could address the microangiopathic injury, neuroinflammation, mitochondrial dysfunction, and endothelial damage underlying Long COVID symptoms — had substantial theoretical support.

By 2025, more than 21 clinical studies, including 10 randomized controlled trials, had evaluated HBOT for long COVID. (PMC: HBOT on Long COVID Symptoms) The most rigorous of these, including Hadanny et al. (2024) and a phase II RCT by Kjellberg et al. in Sweden with 80 subjects, reported significant and durable improvements in fatigue, cognitive function, quality of life, and pain, with clinical benefits observed up to one year after the last treatment. A systematic review by esmed.org characterized HBOT as "the only known single treatment that can improve or reverse the many symptoms across multiple organ systems that define Long COVID." (ESMED: HBOT Treatment of Long COVID) The evidence, while promising, remains incompletely consolidated; large-scale multi-center trials are ongoing.

Part VIII: Famous Chambers — A Gallery of Hyperbaric Landmarks

Cunningham's Steel Ball, Cleveland (1928–1942): The largest hyperbaric chamber ever constructed. 65 feet in diameter, 5 stories, 900 tons. Site: 18485 Lake Shore Boulevard, Cleveland. Built for $1 million; dismantled for $25,000 in scrap metal. Its ghost endures in every textbook.

Duke University F.G. Hall Laboratory, Durham, NC (est. 1963, expanded 1968): Six large chambers, depths simulated to 1,000 feet seawater. Site of the Atlantis saturation dives (69.5 ATA, 1978–1984). Over 1,000 scientific publications. The center was formally designated the Center for Hyperbaric Medicine and Environmental Physiology in 1998. (Duke Anesthesiology: History of Duke Chambers)

Boerema's Amsterdam Operating Chamber (est. 1956): The University of Amsterdam's hyperbaric surgical suite where Life Without Blood was conceived and where the first gas-gangrene patients were treated. The cradle of modern hyperbaric medicine.

Sagol Center, Assaf Harofeh Medical Center, Zerifin, Israel (est. 1990s): The most productive clinical research hyperbaric program of the twenty-first century. Site of the Efrati/Hadanny neuroplasticity, cognitive aging, and Long COVID trials. Affiliated with Tel Aviv University.

Timeline Summary

Epilogue: The Long Arc

Hyperbaric oxygen therapy has traveled a remarkable distance from Nathaniel Henshaw's unbuilt conceptual chamber to the randomized controlled trials of Tel Aviv and Gothenburg. It has been condemned as quackery and proven to save lives; it has been the province of luxurious spas, eccentric millionaires, naval officers, and Nobel-adjacent physiologists. Each era contributed something essential: the Victorians the infrastructure; Paul Bert the physics; Haldane the safety framework; Boerema the evidence; the UHMS the standards; Efrati the neurobiological theory.

What has not changed in three and a half centuries is the central intuition — that the same air we breathe, applied with precision and pressure, might do more than merely keep us alive. The twenty-first century is now testing that intuition against the most rigorous scientific standards ever brought to bear on it. The outcome of those trials, particularly in long COVID, TBI, and cognitive aging, will determine whether hyperbaric oxygen therapy is remembered as one of medicine's most durable ideas or its most resilient illusions.

Primary Sources and Citations

1. Bove, K. (2024). "Nathanial Henshaw: Not history's pioneering hyperbaric practitioner." Undersea and Hyperbaric Medicine. https://pubmed.ncbi.nlm.nih.gov/38985147/

2. Krishnamurti, C. (2019). "Historical Aspects of Hyperbaric Physiology and Medicine." InTechOpen. https://www.intechopen.com/chapters/66258

3. Bert, P. (1878). La Pression Barométrique. Masson, Paris. First edition documented at https://www.sophiararebooks.com/pages/books/5284/paul-bert/la-pression-barometrique

4. Paul Bert — Life in Fast Lane (LITFL). https://litfl.com/paul-bert/

5. Wilderness Medicine Society (2024). "History of Diving, Part 3." https://wms.org/magazine/magazine/1483/History-of-Diving-Pt.-3/default.aspx

6. CMAS. "Haldane 1908." https://www.cmas.org/fact-sheets/haldane-1908-eng.html

7. EBSCO Research Starters. "Haldane Develops Stage Decompression." https://www.ebsco.com/research-starters/sports-and-leisure/haldane-develops-stage-decompression-deep-sea-divers

8. Cleveland Historical. "Cunningham Sanitarium." https://clevelandhistorical.org/items/show/378

9. Midtown KC Post. "Why Was There a Huge Steel Tank at 33rd and Harrison?" https://midtownkcpost.com/why-was-there-a-huge-steel-tank-at-33rd-and-harrison-in-the-1920s/

10. Lakeside Press. "Cunningham's Steel Ball, Cleveland." http://www.lakesidepress.com/pulmonary/hyperbaric/textpictures.html

11. OnePager ICU. "Cunningham's Spherical Sanitarium." https://onepagericu.com/blog/spherical-sanitarium-what-can-a-900-ton-steel-sphere-teach-us-about-medicine

12. Boerema, I. (1960). "Life Without Blood." Journal of Cardiovascular Surgery. PubMed: https://pubmed.ncbi.nlm.nih.gov/13802034/

13. Brummelkamp, W.H. et al. (1963). "Treatment of clostridial infections with hyperbaric oxygen drenching." PubMed: https://pubmed.ncbi.nlm.nih.gov/14016240/

14. Smith, G. & Sharp, G.R. (1962). "Carbon Monoxide Poisoning: Treatment by Hyperbaric Oxygenation." JAMA Surgery. https://jamanetwork.com/journals/jamasurgery/fullarticle/566758

15. Ishimaru, H. et al. (2023). "Long-term effects of CO poisoning at Miike Coal Mine." Undersea and Hyperbaric Medicine. https://pubmed.ncbi.nlm.nih.gov/37302076/

16. UHMS 40-Year History Booklet. https://www.uhms.org/images/40th_Anniversary_Booklet.pdf

17. Albert R. Behnke — Wikipedia. https://en.wikipedia.org/wiki/Albert_R._Behnke

18. Duke Anesthesiology. "History of Duke Chambers." https://anesthesiology.duke.edu/hyperbaric-center/chamber/history

19. CMS. "Hyperbaric Oxygen Therapy for Hypoxic Wounds." https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=37&fromdb=true

20. Marx, R.E. et al. (1985). "Prevention of osteoradionecrosis." Journal of the American Dental Association. Review at https://r3healing.com/marx-protocols/

21. DVM360. "Hyperbaric Oxygen Therapy: The History." https://www.dvm360.com/view/hyperbaric-oxygen-therapy-history

22. UHMS. "Idiopathic Sudden Sensorineural Hearing Loss — Approved October 2011." https://www.uhms.org/14-idiopathic-sudden-sensorineural-hearing-loss-new-approved-on-october-8-2011-by-the-uhms-board-of-directors.html

23. Efrati, S. et al. (2013). "Hyperbaric Oxygen Induces Late Neuroplasticity in Post-Stroke Patients." PLOS ONE. https://pmc.ncbi.nlm.nih.gov/articles/PMC3546039/

24. Hachmo, Y. et al. (2020). "Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence." Aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC7746357/

25. Hadanny, A. et al. (2020). "Cognitive enhancement of healthy older adults using hyperbaric oxygen." PubMed: https://pubmed.ncbi.nlm.nih.gov/32589613/

26. Hadanny, A. et al. (2022). "Hyperbaric oxygen therapy improves neurocognitive outcomes in post-COVID." Nature Scientific Reports. https://www.nature.com/articles/s41598-022-15565-0

27. PMC Review (2025). "Hyperbaric Oxygen Therapy on Long COVID Symptoms." https://pmc.ncbi.nlm.nih.gov/articles/PMC12940082/

28. Harch, P.G. et al. (2012). "A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for Blast-Induced Post-Concussion Syndrome." BIA Colorado. https://biacolorado.org/wp-content/uploads/2025/01/Harch-2011-Phase-I-study-of-low-pressure-HBO2-for-blast-induced-PCS-and-PTSD.pdf

29. PMC (2015). "Hyperbaric oxygen in chronic traumatic brain injury." https://pmc.ncbi.nlm.nih.gov/articles/PMC4499900/

30. HMP Global Learning Network. "HBOT: A Brief History." https://www.hmpgloballearningnetwork.com/site/altc/articles/hyperbaric-oxygen-therapy-brief-history-and-review-its-benefits-and-indications-older

Research compiled from primary sources, PubMed, UHMS archives, Cleveland Historical Society, Duke University Medical Center Archives, InTechOpen, and peer-reviewed journals. Word count: approximately 5,400 words.